Inorganic chemistry holds a central role in the management of several diseases both from the diagnostic as well as from the therapeutic point of view. Various platinum drugs are approved at the global or local level for cancer treatment while other transition metals are used for different therapeutic applications or diagnosis. However, even semimetals i.e., the elements which lie on the diagonal connecting boron to polonium are being used in medicine where some compounds with therapeutic properties have been approved by the Food and drugs Administration (FDA) and the European Medicinal Agency (EMA). In the last decades growing attention has been devoted towards tellurium for the preparation of pharmacologically active agents. In this context, Ammonium trichloro(dioxoethylene-O,O′)tellurate (AS101) emerged as a reference tellurium-based compound. This Te(IV) compound is well tolerated in animal models and its peculiar reactivity towards thiol residues of enzymes such as cysteine proteases is at the heart of its pharmacological effects. Actually, AS101 entered several clinical trials due to its good tolerability. In this mini-review the main chemical and biological aspects of this promising metalloid-based drug are briefly summarized and the outcomes as well as future perspectives for the design of improved Te-based compounds are discussed.

AS101: An overview on a leading tellurium-based prodrug

Chiaverini L.
Primo
Writing – Original Draft Preparation
;
Marzo T.
Conceptualization
;
La Mendola D.
Ultimo
Writing – Review & Editing
2022-01-01

Abstract

Inorganic chemistry holds a central role in the management of several diseases both from the diagnostic as well as from the therapeutic point of view. Various platinum drugs are approved at the global or local level for cancer treatment while other transition metals are used for different therapeutic applications or diagnosis. However, even semimetals i.e., the elements which lie on the diagonal connecting boron to polonium are being used in medicine where some compounds with therapeutic properties have been approved by the Food and drugs Administration (FDA) and the European Medicinal Agency (EMA). In the last decades growing attention has been devoted towards tellurium for the preparation of pharmacologically active agents. In this context, Ammonium trichloro(dioxoethylene-O,O′)tellurate (AS101) emerged as a reference tellurium-based compound. This Te(IV) compound is well tolerated in animal models and its peculiar reactivity towards thiol residues of enzymes such as cysteine proteases is at the heart of its pharmacological effects. Actually, AS101 entered several clinical trials due to its good tolerability. In this mini-review the main chemical and biological aspects of this promising metalloid-based drug are briefly summarized and the outcomes as well as future perspectives for the design of improved Te-based compounds are discussed.
2022
Chiaverini, L.; Marzo, T.; La Mendola, D.
File in questo prodotto:
File Dimensione Formato  
Review AS101__R1_clear.docx

accesso aperto

Descrizione: AS101: An overview on a leading tellurium-based prodrug
Tipologia: Documento in Post-print
Licenza: Creative commons
Dimensione 1.12 MB
Formato Microsoft Word XML
1.12 MB Microsoft Word XML Visualizza/Apri
AS101_an Overview on a Leading Tellurium-Based Prodrug.pdf

non disponibili

Descrizione: AS101: An overview on a leading tellurium-based prodrug
Tipologia: Versione finale editoriale
Licenza: NON PUBBLICO - accesso privato/ristretto
Dimensione 1.98 MB
Formato Adobe PDF
1.98 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/1147480
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact